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ing of an antigen-binding domain and a signal transduction
domain. The artificial T cells expressing CAR (CAR-T cells)
are expected to be a useful tool for treatment of various dis-
eases, such as cancer. The addition of a co-stimulatory signal
domain (CSSD) to CAR is shown to be critical for modulating
CAR-T cell activities. However, the interplay among types of
CSSDs, effector functions, and characteristics of CAR-T cells
is largely unknown. To elucidate the interplay, we analyzed
effector functions, differentiation to memory T cell subsets,
exhaustion, and energy metabolism of the CAR-T cells with
different CSSDs. Comparing to the CAR-T cells bearing a
CD28- or 4-1BB-derived CSSD, which are currently used for
CAR-T cell development, we found that the CAR-T cells with
a herpes virus entry mediator (HVEM)-derived CSSD exhibited
enhanced effector functions and efficient and balanced differ-
entiation to both central and effector memory subsets, associ-
ated with an elevated energy metabolism and a reduced level
of exhaustion. Thus, we developed the CAR-T cells bearing
the CSSD derived from HVEM with high functional potency.
The HVEM-derived CSSD may be useful for developing effec-
tive CAR-T cells.
INTRODUCTION
Chimeric antigen receptor (CAR) comprises an extracellular antigen-
binding domain combined with an intracellular signal transduction
domain.1 The first-generation CAR-transduced T (CAR-T) cells
that have CD3z as a signal transduction domain of the CAR often
become anergic and fail to elicit a potent immune response.2 The
second- and third-generation CAR-T cells have been developed by
adding one and two co-stimulatory signal domains (CSSDs) in the
CAR, respectively.1 These CARmolecules with the modular structure
have been shown to successfully mimic the T cell receptor-mediated
signal transduction upon cognate antigen stimulation, leading to pro-
liferation and activation of CAR-T cells.3
The immunotherapy using CD19-targeted CAR-T cells demonstrated
remarkable efficacy against B cell malignancy.4 To expand the possi-
bilities to various clinical applications,5 it may be necessary to further
improve CAR-T cell efficacy. Signaling assumed by the CSSD derivedMolecular Th
This is an open access article under the CC BY-NCfrom co-stimulatory molecules is known be a key event for exhibiting
potent CAR-T cell efficacy.1 However, the effects of CSSDs on CAR-T
cell functions and characteristics are still largely unknown.
Co-stimulatory molecules can be classified into two major families:
the CD28 family, including CD28 and inducible T cell co-stimulator
(ICOS), and the tumor necrosis factor (TNF) receptor superfamily
(TNFRSF), including 4-1BB and herpes virus entry mediator
(HVEM). So far, the CSSD derived from CD28 or 4-1BB has
commonly been used to construct CARs.6 A previous study showed
that the second-generation CAR-T cells with a 4-1BB-derived
CSSD persisted for more than 6 months in the blood of most patients,
whereas the CAR-T cells with a CD28-derived CSSD became mostly
undetectable after 3 months.7 Additionally, 4-1BB co-stimulation
induced enhanced differentiation to the central memory subset
with increased in vitro persistence.8 4-1BB co-stimulation has also
been shown to increase mitochondrial biogenesis and oxidative meta-
bolism for energy production and avert tonic signaling-induced T cell
exhaustion.9 Therefore, the CSSD derived from the TNFRSF appears
to function better than the one from the CD28 family in the context of
second-generation CAR-T cells.
Accumulating reports have suggested potential roles of HVEM,
another member of the TNFRSF, in effector function and memory
development of CD8+ T cells. For example, HVEM deficiency in
CD8+ T cells has been shown to profoundly impair effector CD8+
T cell survival and development of protective immunological mem-
ory.10 An interaction between HVEM expressed on CD8+ T cells
and B- and T-lymphocyte attenuator has also been reported to pro-
mote survival and immunological memory generation in responseerapy: Oncolytics Vol. 14 September 2019 ª 2019 The Authors. 27
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CAR with the HVEM-Derived CSSD Is
Efficiently Expressed in a Human T Cell Line
(A) Schematic representation of the CAR-expressing
lentiviral vector constructs. The CARs contain sCD4 as
antigen recognition domain and differ in CSSD. All lenti-
viral vector constructs express GFP under control of
internal ribosome entry site (IRES). (B) Gating strategy for
CAR expression analysis in the transduced human T cell
line. GFP+-transduced cells were gated (bottom) to
analyze CAR expression (top) with anti-c-myc tag
antibody by flow cytometry. Typical dot plot and CAR
histograms of each transduced cell are shown. Similar
transduction efficiencies were achieved by lentiviral
transduction (see also Figure S1). (C) Bar graph shows
normalized CAR expression level in each CAR-trans-
duced T cell line, which has the indicated CSSD. Each bar
shows the mean with SDs (n = 5). **p < 0.05 (one-way
ANOVA, Bonferroni post hoc). (D) CAR (50 kDa, top), en-
dogeneous CD3z (18 kDa, middle), and actin (43 kDa,
bottom) expression levels in the CAR-transduced T cells
harboring different CSSDs were determined by western
blot with anti-CD3z and anti-actin antibodies, respectively.
Molecular Therapy: Oncolyticsto bacterial infection.11 Additionally, tumor cells that express
anti-HVEM single-chain antibody induce a potent proliferation and
cytokine production of co-cultured T cells.12 These findings have
indicated that HVEM serves as a potent co-stimulatory molecule in
T cells, suggesting that the CSSD derived from HVEM may also be
useful in the context of CAR-T cells.
We generated the HIV Env-targeting CAR-T cells with CSSDs
derived from CD28, 4-1BB, and HVEM, and we examined their
effector functions using HIV Env-expressing target cells. The CAR-
T cells with the HVEM-derived CSSD exhibited higher effector
functions than those with CD28- and 4-1BB-derived CSSDs. Further
analyses showed that the CAR-T cells with the HVEM-derived CSSD
efficiently induced both central and effector memory subsets
with significantly higher glycolysis and mitochondrial respiration
while they averted exhaustion. Therefore, we demonstrate that the
CAR-T cells with the HVEM-derived CSSD exhibit high functional
potency.
RESULTS
CAR with the HVEM-Derived CSSD Is Efficiently Expressed in a
Human T Cell Line
An sCD4, corresponding to 1–178 amino acids of human CD4, was
reported to selectively target HIV-infected cells through binding to
an HIV Env.13 To generate HIV Env-targeting CAR-T cells, we con-
structed lentiviral vectors expressing the CAR in combination with
CSSDs derived from CD28, 4-1BB, and HVEM (Figure 1A). Flow
cytometric analysis indicated that the transduction rates of Jurkat
E6.1 cells with different lentiviral vectors were similar to each other
(Figure S1). On the other hand, the levels of CAR expression on the
cell surface of GFP+ cells differed considerably (Figure 1B), and
they were the highest on the CAR-T cells with the HVEM-derived
CSSD (Figure 1C). Western blot analysis also revealed that amounts28 Molecular Therapy: Oncolytics Vol. 14 September 2019of the CAR with the HVEM-derived CSSD were larger than those
with CD28- and 4-1BB-derived CSSDs in whole-cell lysates
(Figure 1D).
Human T Cell Line Expressing CAR with the HVEM-Derived
CSSD Is Efficiently Activated upon Cognate Antigen Stimulation
To examine functions of the CAR-transduced Jurkat E6.1 cells with
different CSSDs, CD3 target cells (Chinese hamster ovary [CHO]-
GFP or CHO-Env-GFP) were co-cultured with CD3+ Jurkat E6.1
cells, which had been transduced with CAR-expressing lentiviral vec-
tors (Figure S2, left). Then, the GFP and successfully transduced
GFP+ Jurkat E6.1 cells were examined for CD69 upregulation, an
indicator of T cell activation (Figure S2, middle and right). As shown
in Figure 2A, no significant activation was observed in the GFP and
GFP+ Jurkat E6.1 cells upon co-cultivation with control CHO-GFP
cells. The GFP+, but not GFP, Jurkat E6.1 cells were efficiently acti-
vated when CHO-Env-GFP cells were used as target cells (Figure 2A).
Also, measurement of interleukin-2 (IL-2) in the culture supernatants
showed that IL-2 secretion by the CAR-transduced Jurkat E6.1 cells
was induced upon co-cultivation with CHO-Env-GFP cells, but not
with control CHO-GFP cells (Figure 2B). These data demonstrated
that human T cells transduced with the CAR-expressing vectors con-
structed in this study were specifically activated upon cognate antigen
stimulation. Linear regression analysis demonstrated that the per-
centages of activated T cells upon cognate antigen stimulation and
IL-2 secretion were correlated with the levels of CAR expression on
the cell surface (Figures 2C and 2D).
Human Primary T Cell-Derived CAR-T Cells with the
HVEM-Derived CSSD Exhibit Potent Effector Functions
To compare the CAR-T cells with different CSSDs in more detail, we
transduced human primary CD8+ with the CAR-expressing lentiviral
vectors, and we analyzed for their effector functions. Similar to the
Figure 2. HumanTCell Line ExpressingCARwith the
HVEM-Derived CSSD Is Efficiently Activated upon
Cognate Antigen Stimulation
(A) The activated (CD69+) cell percentages in the trans-
duced (CD3+GFP+) or untransduced (CD3+GFP) T cells
were determined by the co-culture assay, with target cells
expressing GFP (CHO-GFP) or HIV Env and GFP (CHO-
Env-GFP) (see also Figure S2). Each bar shows the mean
with SDs from the co-culture assay using the CAR-T cells
with the CD28-, 4-1BB-, and HVEM-derived CSSDs
(n = 6). **p < 0.05 (two-way ANOVA, Bonferroni post hoc).
(B) IL-2 secretion in the co-culture assay was measured
by ELISA. Each bar shows the mean with SDs from
the co-culture assay using the CAR-T cells with the
CD28-, 4-1BB-, and HVEM-derived CSSDs (n = 5). **p <
0.05 (two-way ANOVA, Bonferroni post hoc). (C) Linear
regression analysis between percentages of activated
CAR-T cells (y axis) and the levels of normalized CAR
expression (x axis). (D) Linear regression analysis between
IL-2 secretion from antigen-stimulated CAR-transduced
T cells (y axis) in the co-culture assay and the levels of
normalized CAR expression (x axis).
www.moleculartherapy.orgobservations in Jurkat E6.1 cells (Figures 1B–1D), the CAR expression
levels on the cell surface and in whole-cell lysate were the highest for
the CAR-T cells with the HVEM-derived CSSD and the lowest for
those with the CD28-derived CSSD (Figures 3A–3C and S3). We
also compared the effector functions of the CAR-T cells with different
CSSDs. Although all of the three CAR-T cells led to antigen-specific
cytotoxic activities against HIV Env-expressing target cells, the CAR-
T cell with the HVEM-derived CSSD exhibited the highest activity
(Figure 3D). Similarly, the highest levels of cytokines, such as IL-2,
TNF-a, and interferon (IFN)-g, were secreted from the CAR-T cells
with the HVEM-derived CSSD compared to the other CAR-T cells
tested in this study (Figure 3E). Comparable with the observations
in Jurkat E6.1 cells (Figures 2C and 2D), effector functions of the
CAR-T cells measured by cytotoxic activities and cytokine secretions
were correlated with the levels of CAR expression on the cell surface
(Figures 3F and S4). Thus, the CAR-T cells with the HVEM-derived
CSSD appeared to be potent.
CAR-T Cells with the HVEM-Derived CSSD Efficiently
Differentiate to Both Central and Effector Memory Subsets
Relative proportions of memory subsets in CAR-T cells have been
suggested to affect their function and persistence in vivo.14,15 Partic-
ularly important memory subsets for protective immunity are known
as central memory (TCM, CD45RO
+CCR7+) and effector memory
(TEM, CD45RO
+CCR7) T cells.16 We thus analyzed proportions ofMolecular Thmemory T cell subsets by surface expression of
CD45RO and CCR7 (Figure 4A). Whereas the
control T cells dominantly contained the TEM
subset, the CAR-T cells with different CSSDs
showed larger percentages of the TCM subset
(Figure 4A). In comparison among the CAR-Tcells with different CSSDs, the CAR-T cells with CD28- and 4-1BB-
derived CSSDs dominantly contained the TEM and TCM subsets,
respectively (Figure 4B). Interestingly, the CAR-T cells with the
HVEM-derived CSSD contained equivalent percentages of TCM and
TEM subsets (Figure 4B), suggesting that the HVEM-derived CSSD
efficiently induced both TEM and TCM subsets.
CAR-T Cells with the HVEM-Derived CSSD Avert T Cell
Exhaustion
Prolonged stimulation of T cells has been known to cause exhaustion
characterized by decreased proliferation, lowered levels of cytokine
production, high rates of apoptosis, and expression of inhibitory re-
ceptors, such as programmed cell death 1 (PD-1) and lymphocyte
activation gene 3 (LAG-3).17,18 To determine the effect of CSSDs
on T cell exhaustion, we examined the percentages of PD-1+,
LAG-3+, and PD-1+/LAG-3+ exhausted T cell populations (Figures
5A and 5B). The results showed that the CAR-T cells with the
CD28-derived CSSD contained relatively large percentages of
exhausted T cells, whereas those with the 4-1BB-derived CSSD con-
tained significantly lower percentages of exhausted T cells at days 9
and 16 after transduction (Figures 5C and 5D). The LAG-3+ popula-
tion, but not the PD-1+/LAG3+ population, was induced in the
CAR-T cells with the HVEM-derived CSSD compared to control
T cells at day 9 after transduction (Figure 5C). Moreover, the
CAR-T cells with the HVEM-derived CSSD contained the lowesterapy: Oncolytics Vol. 14 September 2019 29
Figure 3. CAR-T Cells with the HVEM-Derived CSSD Exhibit Potent Effector Functions
(A) Comparison of cell surface CAR expression among the CAR-T cells with different CSSDs. CAR expression in GFP+-transduced primary human CD8 T cells was analyzed
with anti-c-myc tag antibody by flow cytometry. Representative histograms of CAR expression (x axis) in GFP+ cells are shown. The number in each histogram shows MFI of
the CAR. (B) Bar graph shows normalized CAR expression level in each CAR-T cell with the indicated CSSD. Each bar shows the mean with SDs (n = 6). **p < 0.05 (one-way
ANOVA, Bonferroni post hoc). (C) CAR (50 kDa, top), endogeneous CD3z (18 kDa, middle), and actin (43 kDa, bottom) expression levels in the CAR-T cells with different
CSSDs were determined by western blot with anti-CD3z and anti-actin antibodies, respectively. (D) The CAR-T cells with different CSSDs were co-cultured with CHO-GFP
(open circle) or CHO-Env-GFP (filled circle) cells at effector-to-target (E:T) ratios of 10:1, 5:1, and 1:1. The lactate dehydrogenase release into the culture supernatant was
measured, and the cytotoxicity (% lysis) was calculated. The results show the mean of two separate experiments with primary CD8 T cells from two different healthy human
donors (n = 6). (E) Bar graph shows IL-2 (left), TNF-a (middle), and IFN-g (right) secretion measured by ELISA at an E:T ratio of 10:1 in the co-culture assay (n = 6). **p < 0.05
(one-way ANOVA, Bonferroni post hoc). (F) Linear regression analysis between TNF-a secretion (y axis) in the co-culture assay and the levels of normalized CAR expression
(x axis) among the CAR-T cells with different CSSDs. (See also Figure S4 for linear regression analysis of IL-2, IFN-g, and cytotoxicity.)
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Figure 4. CAR-T Cells with the HVEM-Derived CSSD
Efficiently Differentiate to Both Central and Effector
Memory Subsets
(A) Representative plots shows the cell surface expression
of CD45RO (x axis) and CCR7 (y axis) on the CAR-T cells
with different CSSDs. Control shows CD8 T cells trans-
duced only with GFP. (B) Bar graph shows T cell
subsets, including naive (N, CCR7+CD45RO), central
memory (CM, CCR7+CD45RO+), effector memory (EM,
CCR7CD45RO+), and terminally differentiated effector
memory (TEMRA, CCR7CD45RO) among the CAR-
T cells with different CSSDs. The mean with SDs of two
separate experiments with primary CD8 T cells from
two different donors are shown (n = 6). **p < 0.05 (two-
way ANOVA, Bonferroni post hoc).
www.moleculartherapy.orgpercentage of exhausted T cells among the CAR-T cells tested in
this study at day 16 after transduction (Figure 5D). Interestingly,
the percentages of PD-1+ and LAG-3+ cells were larger and
smaller, respectively, for the CAR-T cells with the HVEM-derived
CSSD than those with the 4-1BB-derived CSSD at day 16 after
transduction (Figure 5D). Taken together, these data suggested that
the CAR-T cells with the HVEM-derived CSSD averted T cell
exhaustion.
CAR-T Cells with the HVEM-Derived CSSD Exhibit
Reprogrammed Energy Metabolism
It has recently been shown that T cell exhaustion was accompanied
by deficient energy metabolism.19,20 Thus, we compared metabolic
states of the CAR-T cells with different CSSDs at basal condition
and following the serial addition of reagents to analyze relative
contribution of mitochondrial and non-mitochondrial mechanisms
of oxygen consumption (Figure 6A). Mitochondrial respiration and
glycolysis can be measured by oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR), respectively. The
CAR-T cells with the HVEM-derived CSSD showed the highest
level of basal OCR, followed by those with the 4-1BB-derived
CSSD and the control T cells; those with the CD28-derived CSSD
showed the lowest level of basal OCR (Figure 6B). We also
measured ATP-linked respiration by adding an ATP synthase inhib-
itor oligomycin and maximal OCR levels by adding carbonyl cya-
nide-4 (trifluoromethoxy) phenylhydrazone (FCCP; uncoupling of
oxygen consumption from ATP production) (Figure 6A). The re-
sults indicated that ATP-linked respiration and maximal OCR levels
in the different CAR-T cells were similarly elevated as basal OCR
levels (Figures 6C and 6D). Interestingly, basal ECAR was signifi-
cantly increased only for the CAR-T cells with the HVEM-derived
CSSD (Figure 6E). These data indicated that the CAR-T cells with
the CD28-derived CSSD exhibited a low-energy state, whereas those
with the 4-1BB-derived CSSD induced higher mitochondrial respi-
ration. Moreover, the CAR-T cells with the HVEM-derived CSSD
induced enhanced glycolysis as well. These results suggested that
the HVEM-derived CSSD could lead to reprogramming of energy
metabolism.DISCUSSION
We developed lentiviral vectors expressing the CAR consisting of
sCD4 as an antigen recognition domain combined with CSSDs
derived from CD28, 4-1BB, and HVEM. Transducing the human
T cell line and primary T cells with these vectors, we demonstrated
that the CSSD in CAR construct was a crucial determinant for the
levels of CAR expression on the cell surface, which appeared to be
correlated with the activities and effector functions of the CAR-T cells.
It was also shown in this study that T cell exhaustion, energy meta-
bolism, and induction of the memory T cell subsets were also affected
by the CSSD in CAR constructs. Among the CSSDs examined in this
study, the HVEM-derived CSSD led to the highest level of CAR
expression, most potent effector functions of CAR-T cells, evasion
of exhaustion, and balanced induction of both central and effector
memory T cell subsets, associated with elevated glycolysis and mito-
chondrial respiration. The results of this study suggest that the
HVEM-derived CSSD may be useful for generating effective CAR-
T cells in a certain context.
It is unknown yet how the CSSD controls the level of CAR expression
on the cell surface. Since amounts of CAR molecules in whole-cell
lysate were correlated to the level of the cell surface expression, CAR
synthesis rather than trafficking might be affected by the CSSD.
Among other possibilities, different CSSDs might activate different
signaling pathways, resulting in distinct levels of gene expression.
For example, CD28-mediated co-stimulation induces the phosphoi-
nositide 3-kinase (PI3K)-Akt pathway, whereas 4-1BB-mediated co-
stimulation primarily activates c-Jun N-terminal kinase (JNK) and
p38 through TNFR-associated factors.21,22 It has also been shown
that 4-1BB and HVEM are capable of activating alternative nuclear
factor kB (NF-kB) pathways.23 These differences in signaling path-
ways may affect the CAR expression at a transcriptional or transla-
tional level.24
Antigen-independent tonic signaling during ex vivo expansionhas been
shown to cause exhaustion of the CAR-T cells with the CD28-derived
CSSD, whereas those with the 4-1BB-derived CSSD are relatively re-
fractory to exhaustion.9 Our studies not only confirmed theseMolecular Therapy: Oncolytics Vol. 14 September 2019 31
Figure 5. CAR-T Cells with the HVEM-Derived CSSD
Avert CAR-T Cell Exhaustion
(A and B) Representative plots shows cell surface
expression of PD-1 (x axis) and LAG-3 (y axis) on the
CAR-T cells with different CSSDs at days 9 (A) and 16 (B).
The numbers in each plot show percentages of each
population in the CAR-T cells with different CSSDs.
Control shows CD8 T cells transduced only with GFP.
(C and D) Bar graph shows the percentages of the
CAR-T cell populations that express one or two inhibitory
receptors (PD-1 and LAG-3) at days 9 (C) and 16 (D). The
mean with SDs of two separate experiments with primary
CD8 T cells from two different healthy human donors are
shown (n = 6). **p < 0.05 (one-way ANOVA, Bonferroni
post hoc).
Molecular Therapy: Oncolyticsobservations but also demonstrated that the HVEM-derived CSSD
could avert CAR-T cell exhaustion. In addition, our data suggested
that CSSDs in CAR constructs could affect the degrees of T cell exhaus-
tion through differential effects on the inhibitory receptor expression
(Figure 5B). Since 4-1BB and HVEM are classified in the TNFRSF, it
is possible that the CSSD derived from the TNFRSF, but not from the
CD28 family, might allow CAR-T cells to avoid exhaustion.
Mitochondrial dynamics have been suggested to control T cell fate
through metabolic programming.25 In addition, 4-1BB-mediated co-
stimulation has been reported to enhance mitochondrial respiration
with increased central memory subsets.8 Our results were compatible
with these previous studies, and they also demonstrated that the
HVEM-derived CSSD enhanced both glycolysis and mitochondrial
respiration and yielded relatively low levels of T cell exhaustion as
well. It has also been shown that various T cell subsets require distinct
metabolic programs to support their function.26–28 Our data suggested
that co-stimulation signals impacted differentiation of theCAR-T cells
to central and effector memory T cell subsets and that the HVEM-
derived CSSD induced efficient and balanced differentiation. Different
co-stimulatory signals are likely to affect metabolic programs in
distinct manners to differentiate specific memory T cell subsets.
Development of new anti-HIV drugs and progress in anti-retroviral
therapy (ART) dramatically improved the prognosis of HIV-infected
patients. However, it has not been successful for ART to completely32 Molecular Therapy: Oncolytics Vol. 14 September 2019eliminate HIV from the patient’s body due to
persistence of latently infected cells. To achieve
this goal, the so-called “shock-and-kill”
approach, which combines pharmacological re-
activation of the latently infected cells and
following immunotherapies with HIV-specific
cytotoxic T lymphocytes (CTLs) or broadly
neutralizing antibodies (bNAbs), has been pro-
posed.29 In this protocol, CD4-based CAR-T
cells targeting the conserved region of HIV-1
Env might be more useful than T cell receptor
(TCR)-based or bNAb-based CAR-T cells,which fail to recognize the antigens with escape mutations. In fact,
a recent study reported promising results of the CAR-T cells
harboring a 4-1BB-derived CSSD in the in vitro and in vivo models
of HIV treatment.30 The results of our study strongly suggest that
the CD4-based CAR-T cells with the HVEM-derived CSSD, which
showed more potent effector functions than those with the CD28-
and 4-1BB-derived CSSDs, may also be a useful tool for the shock-
and-kill treatment of HIV infection.
Our results showed that CAR expression levels were clearly associated
with effector functions in Jurkat T cells (Figures 2C and 2D) and CD8
T cells (Figures 3F and S4) under similar transduction efficiencies
(Figures S1 and S3), suggesting that CAR expression level could be
the major contributor for the higher effector functions. Since CAR
expression was different among CAR-T cells with different CSSDs,
it is very hard to determine whether the CAR expression or the
biological functions of CSSDs mainly affect CAR-T cell effector func-
tions and characteristics using this experimental system. However,
the biological functions of CSSDs might affect CAR-T cell character-
istics, such as T cell exhaustion and memory phenotype, because the
type of CSSD, but not CAR expression level, was associated with these
CAR-T cell characteristics (Figures 4 and 5).
To further determine this issue, adjusting CAR expression levels in
CAR-T cells with different CSSDs may be necessary in future studies
using the appropriate experimental system. In addition, while our data
Figure 6. CAR-T Cells with the HVEM-Derived CSSD Exhibit Reprogrammed Energy Metabolism
(A) TheOCRs of the CAR-T cells with different CSSDs under basal metabolic conditions and in response tomitochondrial inhibitors, as specified in theMaterials andMethods.
The data are the summary of two experiments performed with the CAR-T cells made from two different healthy human donors and plotted as mean with SDs. Control shows
CD8 T cells transduced only with GFP. (B–E) Basal OCR levels (B), basal ECAR levels (C), ATP-linked respiration (D), and maximal OCR levels (E) are shown. Bar graph
shows the mean with SDs of two separate experiments with the CAR-T cells made from two different healthy human donors (n = 5). **p < 0.05 (one-way ANOVA, Bonferroni
post hoc).
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CAR with sCD4 as an antigen-binding domain, it is unknown yet
whether the HVEM-derived CSSD is universally versatile. Further
studies will be necessary to examine the effects of the HVEM-derived
CSSD on activities and functions of CAR-T cells with various antigen
specificities. Also, the CD4-based CAR-T cells have been shown to
have no potential toxicities in a humanized mouse model31 and clin-
ical trials.32 However, it may also be necessary to test, in the future, the
potential toxicities of the CD4-based CAR-T cells with the HVEM-
derived CSSD, because they secreted a relatively larger amount of cy-
tokines than those with the CD28- and 4-1BB-derived CSSDs.
In summary, our results demonstrate that the CSSD in CAR is a
crucial determinant for effector functions and characteristics of
CAR-T cells, indicating that the CSSD in CAR is important for
designing more potent CAR-T cells. Moreover, the HVEM-derived
CAR-T cells may be a promising candidate for generating effective
CAR-T cells.MATERIALS AND METHODS
Study Approval
This study was conducted according to the principles of the Declara-
tion of Helsinki and with the approval of the Scientific Ethics
Committee of the Dokkyo Medical University. Written informed
consent was obtained from all subjects after oral explanation of this
study.
Cell Culture
The culture media, minimum essential medium (MEM), DMEM, and
RPMI (Thermo Fisher Scientific, Waltham, MA), were supplemented
with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific),
2 mM glutamine (Thermo Fisher Scientific), 10 U/mL penicillin,
and 10 mg/mL streptomycin (Thermo Fisher Scientific) and
named shortly M10, D10, and R10, respectively. CHO cells and their
transfectants were maintained in M10 supplemented with non-
essential amino acid (M10-NEAA). 293FT cells were cultured in
D10, and Jurkat E6.1 cells, obtained from European Collection ofMolecular Therapy: Oncolytics Vol. 14 September 2019 33
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R10. Human peripheral blood mononuclear cells (PBMCs) from
healthy donors were prepared by Ficoll-Paque (GE Healthcare Life
Sciences, Pittsburgh, PA) density gradient and cultured in AIM-V
(Thermo Fisher Scientific) supplemented with 5% FBS and 10 mM
HEPES (shortly, complete AIM-V) overnight to remove plastic-
adherent monocytes. Monocyte-depleted PBMCs were used for trans-
duction experiments. All cells were grown at 37C with 5% CO2.
Vector Constructions
To introduce multiple restriction enzyme sites, a DNA linker was
introduced into lentiviral vector plasmid pTK643-CMV-IRES-
GFP/blastcidine (BSD). The DNA linker containing XbaI-XhoI-
BsiWI-BstBI-BamHI restriction enzyme sites was made by incubating
two oligonucleotides, L1 (50-CTAGACTCGAGCGTACGTTCGA
AG-30) and L2 (50-GATCCTTCGAACGTACGCTCGAGT-30), at a
molar ratio of 1:1 at 70C for 10 min and left at room temperature
for 2 h. The linker DNA was inserted into XbaI/BamHI-digested
pTK643-CMV-IRES-GFP/BSD (resulting in pTK643-CMV-MCS-
IRES-GFP/BSD).
For making the sCD4-encoding DNA fragment, total RNA extracted
from Jurkat E6.1 cells by ISOGEN (Nippon Gene, Tokyo, Japan) was
used for cDNA synthesis with ReverTra Ace (Toyobo, Osaka, Japan),
according to the manufacturer’s instructions. The sCD4 DNA
fragment containing XbaI/EcoRI sites was amplified using KOD-FX
(Toyobo) with the following primers: sCD4 forward, 50-GAATCTA
GAGCCACCATGAACCGGGGAGTC-30; and sCD4 reverse, 50-
GATCTTGAATTCAGCTAGCACCACGATGTC-30. Purified DNA
fragment was incubated with Ampli Taq (Thermo Fisher Scientific,
Waltham, MA) at 72C for 10 min to add A tails. The A-tailed
DNA fragment was ligated into pGEM-T easy vector (Promega,
Madison, WI). The sequence was verified with BigDye Terminator
version (v.)3.1 Cycle Sequencing Kit (Thermo Fisher Scientific).
The cDNA fragments encoding CSSDs derived from CD28,
4-1BB, and HVEM were artificially synthesized by GenScript (Piscat-
away, NJ). To make sCD4-CAR-expressing lentiviral vectors, the
XbaI/EcoRI-digested sCD4 DNA fragment and each of the EcoRI/
BamHI-digested CSSD DNA fragments were ligated into XbaI/
BamHI-digested pTK643-EF1a-IRES-GFP/BSD.
For making the HIV Env- (NL4-3 strain) expressing lentiviral vector
plasmid, XbaI/XhoI-digested pRE11-NL43, kindly provided by Dr.
Noriaki Hosoya,33 was ligated into XbaI/XhoI-digested pTK643-
CMV-MCS-IRES-GFP/BSD.
Recombinant Lentivirus Production
Recombinant lentivirus was produced as previously described34 with
some modification. Briefly, 293FT cells were cultured on a collagen-
coated 10-cm dish (Iwaki, Shizuoka, Japan) with 80%–90% conflu-
ency. The culture medium was replaced to D10 containing 25 mM
chloroquine (Sigma, Darmstadt, Germany) without antibiotics.
Regarding vectors packed withDNRF, the following plasmid amounts34 Molecular Therapy: Oncolytics Vol. 14 September 2019were used: 15 mg lentiviral vector plasmid, 10 mg DNRF, and 5 mg
pMD.G. The plasmids were co-transfected into 293FT cells with
polyethyleneimine (PEI) MAX (Polysciences, Warrington, PA) at a
DNA-to-PEI ratio of 2:1. The supernatant was replaced with D10
containing 5 mM sodium butylate (Wako Pure Chemicals Industries,
Osaka, Japan) and 10 mM forskolin (Tokyo Chemical Industry,
Tokyo, Japan). The culture supernatants containing recombinant
lentiviruses were harvested at 48 h after transfection and cleared by
centrifugation and 0.45-mm filtration (Millipore, Burlington, MA).
The recombinant lentiviruses were concentrated by high-speed
centrifugation at 18,000 rpm for 3 h using Himac CR21N (Hitachi
Koki, Tokyo, Japan). The lentiviral titers were measured on HeLa cells
based on the percentage of GFP-positive cells by flow cytometry.
Transduction with Lentiviral Vectors
The recombinant lentivirus-containing supernatant was used to
transduce CAR and GFP genes into Jurkat E6.1 cells and HIV Env
gene into CHO cells, respectively. Briefly, 2 million Jurkat E6.1 cells
or semi-confluent CHO cells in a 6-well plate were exposed to
1 mL unconcentrated lentivirus-containing supernatant in the
presence of polybrane at 8 mg/mL. The cells were centrifuged at
5,500 rpm for 3 h at 22C to enhance viral infection. After removal
of the supernatant, the cells were cultured at 37C in a CO2 incubator
for 48 h. The culture medium was replaced with the media supple-
mented with 10 mg/mL BSD. Thereafter, transduced cells were main-
tained in the media with 10 mg/mL BSD until the following assays
were performed.
Human primary CD8 T cells were isolated from monocyte-depleted
PBMCs with anti-human CD3-allophycocyanin (APC), CD4-phy-
cierythrin (PE), and CD8-PE/Cy7 antibodies (all from BioLegend,
San Diego, CA) by cell sorting on a FACS Aria II (BD Biosciences,
Franklin Lakes, NJ), and they routinely achieved >95% purity. The
purified CD8 T cells were activated with anti-CD3/CD28 beads
(Thermo Fisher Scientific) at a bead-to-cell ratio of 3:1 in complete
AIM-V supplemented with 40 U/mL recombinant human IL-2
(obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, from Dr. Maurice Gately, Hoffmann-La Roche) for
3 days. After removal of the anti-CD3/CD28 beads, activated CD8
T cells were transduced with concentrated recombinant lentivirus
on days 3 and 4 using Retronectin- (Takara Bio, Shiga, Japan) coated
plates, according to the manufacturer’s instructions. The cells trans-
duced only with GFP were used as a control. Thereafter, the cells
were cultured for 16 days with fresh media containing 300 U/mL
IL-2 replenished every 2–3 days. Successfully transduced GFP+ cells
were sorted at 16 days after the initial anti-CD3/CD28 bead stimula-
tion for energy metabolism analysis.
Flow Cytometry
Antibodies used in flow cytometry were obtained from BioLegend
otherwise indicated. CAR expression on the transduced Jurkat E6.1
cells was analyzed with anti-c-myc tag antibody (Santa Cruz Biotech-
nology, Dallas, TX), followed by anti-mouse immunogloburins (Igs)-
PE antibody (Agilent Technologies, Santa Clara, CA). Activation of
www.moleculartherapy.orgthe CAR-transduced Jurkat E6.1 cells in the co-culture assay was
analyzed with anti-human CD3-APC antibody and CD69-PE
antibody (see Figure S1 for gating strategy). CAR expression on
CAR-transduced primary CD8+ T cells was analyzed with bio-
tinylated anti-c-myc tag antibody followed by streptavidin-PE (Tonbo
Biosciences, San Diego, CA). For normalizing CAR expression by
GFP expression, we divided the mean fluorescence intensity (MFI)
of CAR by the MFI of GFP. This value was represented as normalized
CAR expression. Exhaustion of the CAR-T cells was analyzed with
anti-human PD-1-APC antibody and anti-human LAG-3-PE/Cy7
antibody (Thermo Fisher Scientific). Memory phenotypes of the
CAR-T cells were analyzed with CD45RO-PE, CD8-PE-Cy7, and
CCR7-APC. The centrifuged cells were resuspended with antibody
diluted in fluorescence-activated cell sorting (FACS) buffer (PBS con-
taining 2% FBS and 0.02% sodium azide) and incubated on ice for
30 min. After washing with ice-cold FACS buffer, the cells were fixed
with 1% paraformaldehyde in PBS and analyzed with a FACS Calibur
(BD Biosciences).
Western Blot
Cells (5  106) were washed once with ice-cold PBS, resuspended in
150 mL radioimmunoprecipitation assay (RIPA) buffer (10 mM
TrisHCl [pH 7.4], 1% NP-40, 0.1% Sodium Deoxychorate, 0.1%
SDS, 0.15 M NaCl, and 1 mM EDTA), supplemented with Complete
Mini (Roche, Mannheim, Germany) and 1 mM PMSF, and incubated
on ice for 30 min. The cell lysate cleared by centrifugation (20 mL) was
mixed with NuPAGE LDS sample buffer (Thermo Fisher Scientific)
and 0.1 M DTT and boiled at 95C for 5 min. Boiled samples were
separated by electrophoresis in a NuPAGE 10% Bis-Tris gel (Thermo
Fisher Scientific) and transferred to an Immobilon P membrane
(Millipore, Burlington, MA). The membrane was blocked with the
blocking buffer (5% non-fat dried milk and 0.1% Tween-20 in Tris-
buffered saline [TBS]) for 30 min. Blocked membrane was incubated
at 4C overnight with anti-actin antibody (I-19) or anti-CD3zeta anti-
body (F-3) (Santa Cruz Biotechnology, Dallas, TX) diluted in a block-
ing buffer. The membrane was then incubated for 1 h with anti-goat
immunoglobulin G (IgG)-horseradish peroxidase (HRP) (Millipore)
or anti-mouse IgG-HRP (GE Healthcare, Buckinghamshire, UK)
diluted in a blocking buffer. The membrane was washed three times
with 0.1% Tween-20/TBS after all antibody incubation steps.
Immunoreactivity was visualized with a Lumi-Light PLUS (Roche)
as a substrate and detected with Light-Capture II (ATTO, Tokyo,
Japan).
Co-culture Assay
Activation and IL-2 secretion of the CAR-transduced Jurkat E6.1 cells
were determined by co-culturing with target cells (CHO-GFP or
CHO-Env-GFP). Target cells (1  105) were seeded in each well of
a 96-well flat-bottom plate. CAR-transduced Jurkat E6.1 cells (2 
105) were added and co-cultured overnight. On the next day, the cul-
ture supernatants including cells were harvested and centrifuged to
separate cells and cell-free supernatants. IL-2 secretion into the super-
natant was measured using Human IL-2 ELISA MAX Deluxe
(BioLegend), according to the manufacturer’s instructions. The re-maining cells were used to determine CD69 expression by flow
cytometry.
To determine cytotoxicity of the CAR-T cells, target cells (1  104)
were seeded in each well of a 96-well flat-bottom plate. The CAR-T
cells were added at different effector-to-target ratios (see also in the
figure legend) and co-cultured in phenol red-free R10 with NEAA.
After overnight incubation, the cell-free supernatant was collected
by centrifugation. Lactate dehydrogenase release in the supernatant
was assayed using CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega). The cytotoxicity (% lysis) was calculated according to
the manufacturer’s instructions. In cases of unequal percentages of
CAR-transduced cells in the cultures, untransduced T cells were
added to ensure that both the number of CAR+ T cells and the total
number of T cells remained consistent across the CAR-T cell groups.
Collected supernatants were also used to determine IL-2, TNF-a, and
IFN-g secretion using human IL-2, TNF-a, and IFN-g ELISA MAX
Deluxe (all from BioLegend), according to the manufacturer’s
instructions.Analysis of Energy Metabolism
Mitochondrial function of the CAR-T cells was analyzed with an
extracellular flux analyzer XFp (Agilent Technologies, Santa Clara,
CA). Each well of the cell culture microplate was coated with CellTak
(BD Biosciences), according to the manufacturer’s instructions. To
assay mitochondrial function, the sorted CAR-T cells without further
culture were resuspended in XF RPMI medium supplemented with
5.5 mM Glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate,
and they were seeded at 3  105 cells/well. The plate was centrifuged
at 200  g for 1 min and incubated at 37C in a non-CO2 incubator
for 30–60 min. During incubation, the instrument XFp and its assay
cartridges were calibrated according to the manufacturer’s instruc-
tions. OCRs were measured under basal conditions and following
treatment with 1 mM oligomycin (an inhibitor of ATP synthase),
1 mM FCCP (uncoupling of oxygen consumption from ATP produc-
tion), and 1 mM rotenone and antimycin A (inhibitor for complexes I
and III of the electron transport chain, respectively) (XFp Cell Mito
Stress Kit, Agilent Technologies). Four measurements of basal
condition and after each treatment were performed. ATP-linked
respiration was defined as (last rate measurement before oligomycin
addition) (minimum rate measurement after oligomycin addition).
Maximal OCR was measured after FCCP treatment.Statistics
Statistical analysis was described previously.35,36 Unpaired one-way
or two-way ANOVA with Bonferroni multiple comparison test and
linear regression analysis were performed, and R2 value was
calculated using GraphPad Prism (GraphPad, San Diego, CA). A
p value < 0.05 was considered statistically significant.SUPPLEMENTAL INFORMATION
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